Citations

Clear

6273 citation(s) found for "To, Andrew".

Clinical evaluation of adults undergoing elective surgery utilizing intraoperative incisional wound irrigation (CLEAN Wound): protocol for a randomised controlled trial
Roke, Rachel , Lillie, Erin , Daneman, Nick , Mason, Stephanie, Jiang, Yidi , Shiroky, Jonah , Puran, Sudarshani, Smith, David E. , Khalil, Jad Abou, Kayssi, Ahmed , Pinchuk, Brian, Apte, Sameer , Lamb, Tyler , Ma, Grace , Vogt, Kelly, Leslie, Kenneth , Mutabdzic, Dorotea, Gómez, David , Ladha, Karim S. , Bennett, Sean, Ullah, Shahnoor M, Holland, Jessica, Smith, Andrew J., Calderone, Michael, Herriott, Judith, Voltan, Ed, Sloan, B., Mazer, C. David , Kennedy, Erin, Aarts, Mary-Anne, Karanicolas, Paul J. , Kayssi, Ahmed , Apte, Sameer S , Lamb, Tyler , Delisle, Megan , Muaddi, Hala , Fergusson, Dean A , Marshall, John C. , Karanicolas, Paul Jack , Tomlinson, George , Serrano, Pablo E , Vogt, Kelly, Tsang, Melanie E. , Ullah, Shahnoor M, Nathens, Avery B.

Mayo Clinic

BMJ Open | July 17, 2025 | Volume: 15 | Issue: 7 | Pages: e104375

10.1136/bmjopen-2025-104375 | PMID 40675632 Get It

Introduction In moderate to high-risk surgical procedures, 15–25% of patients develop a postoperative surgical site infection. Intraoperative incisional wound irrigation has the potential to reduce surgical site infections, and additional randomised controlled trials are required to provide evidence of effectiveness. Methods and analysis This protocol describes a pragmatic, adaptive, participant and adjudicator-blinded trial at 13 sites in Canada in up to 2500 participants. Participants planned for surgery with an abdominal or groin incision, who are eligible and provide verbal consent through an integrated consent model, are randomised to receive intraoperative incisional wound irrigation with povidone-iodine, saline or no irrigation. The primary outcome is surgical site infection within 30 days postoperatively. Secondary outcomes include quality of life measured 30 days postoperatively and morbidity, mortality and healthcare utilisation within 90 days postoperatively. Ethics and dissemination This trial has been approved by the research ethics board at the participating centres and stopped enrolling participants on May 23, 2025. All participants will provide verbal consent. Results will be disseminated via presentation at conferences, publication and posted on clinicaltrials.gov. Trial registration number The study is registered with http://clinicaltrial.gov ( NCT04548661 ; 14 September 2020).
Metagenomic Next-generation Sequencing of Cerebrospinal Fluid: First-year Experience at a Tertiary Referral Hospital
Mulett, Sergio Alvarez , Garcia, Sofia Molina , Saleh, Omar Abu , Rodning, Amanda A, Wengenack, Nancy L. , Patel, Robin , Alvarez Mulett, Sergio , Molina Garcia, Sofia , Abu Saleh, Omar , Wolf, Matthew J, Wengenack, Nancy L , Patel, Robin , Wolf, Matthew J, Norgan, Andrew P.

Mayo Clinic

Clinical Infectious Diseases | July 16, 2025 | Volume: 82 | Issue: 5 | Pages: 808-814

10.1093/cid/ciaf390 | PMID 40668900 Get It

Abstract Background Central nervous system (CNS) infections are significant causes of morbidity and mortality, especially when diagnosis is delayed. Traditional cerebrospinal fluid diagnostic methods for CNS infections have limited sensitivity. Metagenomic next-generation sequencing of cerebrospinal fluid (MSCSF) is a newer diagnostic tool capable of detecting a broad range of pathogens in a single assay. Methods This retrospective cohort study evaluated the first-year experience with MSCSF at Mayo Clinic. A total of 422 tests performed during calendar year 2024 on adult patients at Mayo Clinic facilities and those tested through Mayo Clinic Laboratories were analyzed, with a subcohort analysis of the 210 Mayo Clinic patients performed to define patient characteristics associated with positive results and clinical outcomes. Results The sensitivity of MSCSF for detecting neuroinfection in the subcohort was 64%, with 43% of confirmed neuroinfections diagnosed by MSCSF only. Subjects who were immunosuppressed (odds ratio [OR]: 3.5, P = .008) and those with a high pretest probability of CNS infection (OR: 20.1, P < .001) were more likely to have positive results. Also, those who tested positive were more likely to die within the ensuing 30 days than those who tested negative (OR: 5.2, P = .001). Conclusions MSCSF can be a valuable tool for diagnosing CNS infection but should not be used indiscriminately. It appears to be most beneficial when there is a high clinical suspicion of CNS infection and conventional diagnostics, and available molecular tests, yield negative results. Its integration into clinical practice should be guided by diagnostic stewardship to maximize cost-effectiveness and clinical utility.
Enhancing cognitive function in breast cancer survivors through community-based aerobic exercise training: protocol for a Hybrid Type I effectiveness–implementation study employing a randomised controlled design
Ehlers, Diane K. , Austin, Jessica D. , Page, Lindsey L. , Porter, Gwenndolyn C. , Hickman, Gabriella, McKim, Paul, Cole, Melissa, Donaldson, Maliyah, Braden, B. Blair , Butterfield, Richard , Baxter, Leslie C. , Ahles, Tim A. , Baxter, Leslie C. , Austin, Jessica D , Ernst, Brenda , Ofori, Edward , Fanning, Jason T. , Hickman, Gabriella, Donaldson, Maliyah, Kunze, Katie L. , Estabrooks, Paul Andrew

Mayo Clinic

BMJ Open | July 14, 2025 | Volume: 15 | Issue: 7 | Pages: e104378

10.1136/bmjopen-2025-104378 | PMID 40659404 Get It

Introduction Despite growing evidence to characterise cancer-associated cognitive decline (CACD) in women with breast cancer, interventions to mitigate CACD are limited. Emerging evidence suggests aerobic exercise may enhance cognition after breast cancer diagnosis and treatment; yet, CACD remains an understudied outcome of exercise, and few high-quality studies have been conducted. In addition to knowledge gaps in effectiveness, the translation of exercise interventions to community settings remains challenging. The Breast cancer Reasoning and Activity INtervention (BRAIN) investigates the effectiveness of aerobic exercise training, delivered in a community-based setting, for improving cognitive function in women with breast cancer and gathers information on the implementation success of the intervention. Methods and analysis This Hybrid Type I effectiveness–implementation study is conducted at an academic medical centre in the southwestern United States in partnership with a non-profit, community health and wellness organisation. The study enrols 160 women diagnosed with stage I–IIIa breast cancer and within 3–36 months of treatment completion into a 1:1 randomised controlled trial. Individuals randomised to the exercise group receive a 6-month, individually tailored aerobic exercise programme delivered by exercise trainers employed at local community fitness centres. The programme is progressive in nature and designed to help participants achieve aerobic exercise levels consistent with guidelines for cancer survivors. Individuals randomise to the control group receive a 6-month health education control intervention delivered virtually by hospital-based health educators. Cognitive performance (primary), self-reported cognition, patient-reported outcomes, physical activity and cardiorespiratory fitness are measured at baseline, 6 months (postintervention) and 12 months (follow-up). Brain structure and function are measured via magnetic resonance imaging (MRI) at baseline and 6 months. Implementation outcomes are defined by the RE-AIM framework, which includes reach, effectiveness, adoption, implementation and maintenance. RE-AIM outcomes are measured at baseline, 6 months, 12 months and ongoing during the study. Ethics and dissemination This study was approved by the Mayo Clinic Institutional Review Board (#23-000020). All participants provide informed consent prior to participation. Findings will be disseminated to scientific, clinical and community audiences through manuscripts, presentations and newsletters. Trial registration number NCT04816006.
E-059 Influence of race on extended length of stay following mechanical thrombectomy for anterior circulation stroke
Koo, A, Johnson, Scott, Starke, R, Welch, Babu G. , Rivet, Dennis J. , Graffeo, Christopher S. , Klopfenstein, Jeffrey D., Sahlein, D, Eshraghi, Sheila, Altschul, D, Alaraj, A, Davies, Jason M., Raper, D, Park, M , Malek, Adel M. , Monteith, Stephen J., Eckardt, Glenn S., Beaty, N, Schirmer, C, Arthur, A, Wolfe, S, Chen, C, Church, E, Dornbos, D, Chu, T, Johnson, S, Starke, R, Altschul, David , Ringer, Andrew J. , Hoh, Brian L. , Alaraj, Ali , Mocco, J , Grande, Andrew Walker , Eckardt, G, Beaty, Narlin Bennet , Schirmer, Clemens M., Arthur, A, Dornbos, David

Mayo Clinic

SNIS 22nd annual meeting electronic poster abstracts | July 14, 2025 | Volume: No volume available | Issue: No issue available | Pages: A132.1-A132

10.1136/jnis-2025-snis.175 Get It

Anaplastic large cell lymphoma: unusual clinical and pathologic findings: A report of the 2023 SH-EA4HP Lymphoma Workshop
Marques‐Piubelli, Mario L. , Feldman, Andrew L. , Feldman, Andrew L , Xu, Jie , Hsi, Eric D. , Miranda, Roberto N. , Medeiros, L. Jeffrey

Mayo Clinic

American Journal of Clinical Pathology | July 12, 2025 | Volume: 164 | Issue: 1 | Pages: 110-125

10.1093/ajcp/aqaf029 | PMID 40646678 Get It

Abstract Anaplastic large cell lymphoma (ALCL) cases were discussed at the 2023 Society of Hematopathology/European Association for Haematopathology workshop held on November 9-11, 2023, in Houston, Texas. This session focused on the clinical and pathologic spectrum of 3 types of ALCL: anaplastic lymphoma kinase (ALK)-positive, ALK-negative, and breast implant associated (BIA). Cases of primary cutaneous ALCL were excluded because they were included in another session. Although the diagnosis of ALCL is often straightforward, the 42 submitted cases encompassed unusual clinical presentations, morphologic variants, and atypical immunophenotypes, exemplifying potential difficulties and challenges in establishing the diagnosis of ALCL. Distinguishing ALCL from CD30-positive peripheral T-cell lymphoma, not otherwise specified, or classic Hodgkin lymphoma was discussed. In patients with a previous history of mycosis fungoides and other T-cell lymphoma/leukemia, the differential diagnosis of a CD30-positive T-cell lymphoma mimicking ALCL (mycosis fungoides transformation vs de novo ALCL) was also discussed. In patients with suspected BIA-ALCL, it is critical to properly handle the periprosthetic fluid when the disease first presents and the capsule at the time of initial capsulectomy to make a correct diagnosis and pathologic staging because a missed diagnosis may lead to disease progression. Comprehensive immunohistochemical analysis; fluorescence in situ hybridization for DUSP22, TP63, or JAK2 rearrangement; assessment of clonality of the T-cell receptor and immunoglobulin genes; and sequencing for mutations were performed as part of the workup of the submitted cases, particularly on ALK-negative ALCL cases, emphasizing the importance of ancillary testing in establishing the diagnosis.
Outcomes of Acute Myocardial Infarction in Patients With vs. Without Systemic Lupus Erythematosus
Jabbar, Ali Bin Abdul, Aboeata, Ahmed, Abdul Jabbar, Ali Bin , Ismayl, Mahmoud , Walters, Ryan W. , Goldsweig, Andrew M. , Aronow, Herbert D.

Mayo Clinic

Graduate Medical Education Research Journal | July 11, 2025 | Volume: 7 | Issue: 1 | Pages: 33-34

10.32873/unmc.dc.gmerj.7.1.039 Get It

An anerobic boost to a sub-4-min mile
Kipp, Shalaya , Ramsook, Andrew H. , Joyner, Michael J. , Joyner, Michael J , Ramsook, Andrew H , Kipp, Shalaya

Mayo Clinic

Journal of Applied Physiology | July 11, 2025 | Volume: 139 | Issue: 1 | Pages: 262-262

10.1152/japplphysiol.00452.2025 | PMID 40643409 Get It

Ophthalmic Knowledge Assessment Program Scores and Written Qualifying Examination Performance
Thanitcul, Chanon, Schnabel, Sarah , Bartley, George B., Lee, Andrew G., Crump, Hally, Fajardo, Dale , Peters, Kathryn F., Wilson, Beth, Peters, Kathryn, Srikumaran, Divya S.

Mayo Clinic

JAMA Ophthalmology | July 10, 2025 | Volume: 143 | Issue: 8 | Pages: 678

10.1001/jamaophthalmol.2025.1933 | PMID 40638098 Get It

ImportanceThe Ophthalmic Knowledge Assessment Program (OKAP) has been widely used to determine readiness to take the high-stakes Written Qualifying Examination (WQE). However, it is unclear how well OKAP performance can predict WQE outcomes.ObjectiveTo examine the association between the OKAP and WQE nationally.Design, Setting, and ParticipantsThis was a retrospective cohort study conducted from 2017 to 2022. This national data analysis included residents from ophthalmology residency programs in the US. Study data were analyzed June 2023 to December 2024.ExposuresOKAP and WQE data.Main Outcomes and MeasuresThe national OKAP examination data and the WQE data were matched. Candidates who had complete data for the OKAP during postgraduate year (PGY) 2, 3, and 4 and completed the WQE were included in the study. Two-sample t tests, logistic regression analysis, receiver operating characteristic curves, and confusion matrix were used to examine the association of various test scores (PGY-2 OKAP, PGY-3 OKAP, PGY-4 OKAP, minimum OKAP, maximum OKAP, average OKAP) as predictors for WQE outcomes (pass or fail). Multiple logistic regression analyses were also used to assess the association of gender, time since graduation, program size, and WQE pass/fail outcomes.ResultsA total of 1597 residents (907 male [56.8%]) from 117 residency programs were included in this study. First-time pass rate of the WQE was 89% (1418 of 1597 residents). OKAP scores, particularly average OKAP, maximum OKAP, and PGY-4 OKAP scores (all had area under the curve = 0.88), were the most useful predictor of WQE outcomes. PGY-4 OKAP scores were used for the rest of the analysis for simplicity. A PGY-4 OKAP scaled score of 550 corresponded to 94% of candidates passing the WQE. Using PGY-4 OKAP scores to predict passing/failing, the WQE had 90.7% accuracy. Gender (odds ratio [OR], 1.50; 95% CI, 1.01-2.26; P = .048), program size (OR, 1.55; 95% CI, 0.98-2.41; P = .06), and time since residency graduation (OR, 1.00; 95% CI, 1.00-1.00; P = .14) were not included in the logistic regression model investigating the association of PGY-4 OKAP scores with the likelihood of passing the WQE.Conclusions and RelevanceResults suggest that OKAP examination scores were associated with passing the WQE after adjusting for program size, gender, and time since residency graduation. Further analyses may be warranted to predict failing the WQE so that potential interventions can be attempted.
NCCN Guidelines® Insights: Thyroid Carcinoma, Version 1.2025
Haddad, Robert I. , Bischoff, Lindsay , Applewhite, Megan K. , Bernet, Victor , Blomain, Erik , Brito, Maria , Busaidy, Naifa L. , Campbell, Michael J. , DeLozier, Olivia M. , Duh, Quan‐Yang , Ehya, Hormoz, Grady, Erin C., Hunt, Jason P. , Kandeel, Fouad , Lamonica, Dominick , Lorch, Jochen H. , Mandel, Susan J., Mydlarz, Wojciech K. , Raeburn, Christopher D., Rezaee, Rod , Ritter, Hadley E., Roth, Mara Y. , Salgado, Sarimar Agosto , Scheri, Randall P., Sipos, Jennifer A. , Wirth, Lori J. , Darlow, Susan, Cassara, Carly J., Sliker, Bailee , Haddad, Robert , Guo, Theresa , Haymart, Megan R. , Kotwal, Anupam , Markovina, Stephanie T. , Nabell, Lisle M. , Ridge, John Andrew , Shah, Jatin P. , Sippel, Rebecca S. , Sturgeon, Cord , Wong, Richard J. , Worden, Francis P. , Yeh, Michael W.

Mayo Clinic

Journal of the National Comprehensive Cancer Network | July 10, 2025 | Volume: 23 | Issue: 7 | Pages: No page available

10.6004/jnccn.2025.0033 | PMID 40639400 Get It

The NCCN Guidelines for Thyroid Carcinoma address the management of different types of thyroid carcinoma, including papillary, follicular, oncocytic, medullary, and anaplastic carcinoma. The NCCN Thyroid Carcinoma Panel meets at least annually to review comments from reviewers within their institutions, examine relevant new data from publications and abstracts, and reevaluate and update their recommendations. These NCCN Guidelines Insights focus on the panel’s most recent recommendations regarding systemic therapies for thyroid carcinoma as well as the supporting clinical data.
Adult Cancer Pain, Version 2.2025, NCCN Clinical Practice Guidelines In Oncology
Swarm, Robert A., Youngwerth, Jeanie, Anițescu, Magdalena , Are, Madhuri , Buga, Sorin , Butler, Taylor, Cleary, James F. , Copenhaver, David, Coyne, Christopher , Craig, David S., Finnes, Heidi D. , Greenlee, Heather , Gupta, Mona, Hansen, Eric, Javed, Saba , Kandil, Enas , Mackey, Sean , McGrath, Kathryn, Moryl, Natalie , Nesbit, Suzanne , Noonan, Michael , Norris, Joseph, Pršić, Elizabeth , Rabow, Michael W. , Rickerson, Elizabeth , Sindt, Jill E. , Vorenkamp, Kevin E. , Cunningham, Rebecca, Gurski, Lisa A., Jones, Frankie, Finnes, Heidi, Agne, Julia L. , Butler, Taylor, Chwistek, Marcin , Gupta, Mona, Javed, Saba , McDonald, Andrew, Noonan, Michael, Paice, Judith A. , SMITH, MICHAEL D. , Bruce, Justine Y. , Yoo, Sun

Mayo Clinic

Journal of the National Comprehensive Cancer Network | July 10, 2025 | Volume: 23 | Issue: 7 | Pages: No page available

10.6004/jnccn.2025.0032 | PMID 40639401 Get It

The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Adult Cancer Pain provide recommendations for the comprehensive management of pain in patients with cancer. This article will focus on methods for screening for pain, safe and appropriate prescription of opioid and miscellaneous analgesics, and the optimization of nonpharmacologic interventions including integrative and interventional strategies for treatment of cancer-related pain. Additionally, the NCCN Guidelines discuss methods for the safe reduction of opioids when appropriate, as well as techniques for encouraging the judicious use of opioids. The complete version of the NCCN Guidelines for Adult Cancer Pain addresses additional issues that are not covered here, including management of pain during a pain crisis, management of procedure-related pain and anxiety, pain management for cancer survivors, and the use of nonopioid and adjuvant analgesics for cancer-related pain.